Stereotactic Radiosurgery for Pituitary Neuroendocrine Tumors
Author Information
Author(s): Kim Inhwa, Yan Michael, Sourour Michel, Heaton Robert, Faulkner Colin, Kalyvas Aristotelis, Keilty Dana M., Cusimano Michael D., Payne David, Laperriere Normand, Shultz David B., Alli Saira B., Zadeh Gelareh, Tsang Derek S.
Primary Institution: University Health Network, Toronto, ON Canada
Hypothesis
The study aimed to evaluate outcomes and toxicities of patients with pituitary neuroendocrine tumors treated with stereotactic radiosurgery.
Conclusion
Stereotactic radiosurgery is highly effective for treating recurrent or residual pituitary neuroendocrine tumors, achieving 100% local control with no optic toxicities after a median follow-up of 4.7 years.
Supporting Evidence
- 88 lesions in 83 patients were treated with SRS.
- 100% local control probability was observed with no local tumor recurrences.
- Two- and five-year overall survival estimates were 97% and 95%, respectively.
- 12 patients (14%) developed hypopituitarism after SRS, but no optic neuropathy was reported.
Takeaway
Doctors used a special type of radiation treatment to help patients with certain brain tumors, and it worked really well without causing any eye problems.
Methodology
This was a retrospective, single-institution study of patients treated with frame-based, single-fraction, cobalt-60 stereotactic radiosurgery.
Potential Biases
Selection bias may affect the applicability of results to the general population.
Limitations
The study was limited to a single center and relied on self-reported symptoms for visual toxicities.
Participant Demographics
Median age at diagnosis was 44 years, with 48% male and 52% female participants.
Statistical Information
Confidence Interval
95% CI 89–99 for 2-year overall survival and 95% CI 84–98 for 5-year overall survival.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website